LEN for PrEP: Lessons from Three Early Adopter Countries

Since December 2025, lenacapavir (LEN) for PrEP has been introduced in 10 African countries, hitting introduction milestones with record speed. AVAC, with support from the US Bureau of Global Health Security and Diplomacy (GHSD), partnered with Lvcthealth in Kenya, Pakachere Institute of Health and Development Communication in Malawi, and HEPS-Uganda, along with Ministries of Health (MoH) and the US Embassies in the three countries, to advance community-led demand generation, capacity-building and evidence-informed implementation to speed product introduction.

AVAC is pleased to share our latest impact report, Advancing Access to LEN for PrEP, highlighting the approaches that led to strong community-centered LEN introductions in Kenya, Malawi and Uganda. It documents lessons learned and shares resources to help other countries determine how to effectively prepare for and deliver LEN and future PrEP options. 

In a recent webinar, AVAC was joined by representatives from Ministries of Health and implementing partners who shared rollout experiences and how strategies can be adapted to support choice-centered LEN introduction in other countries. 

“Demand generation is a systems investment, not a campaign. Every time people hear demand generation, the question is what’s the campaign? But we know that this goes way, way beyond just a campaign.”

Patriciah Jeckonia
Lvcthealth

Photo credit: Frontline AIDS

Explore the Executive Summary for a quick overview of achievements and insights and access the full report here. On our country pages, dive into the specific details of how these projects supported LEN rollout in Kenya, Malawi, and Uganda. 

Additional LEN Resources

Building Public Trust Through Evidence-Based Media Engagement 

Advancing Access to LEN 
Learning in Practice: Reports from our Partners — Uganda

The successful introduction of a new HIV prevention technologies depends on health system readiness, public understanding and trust. Journalists play a critical role in translating scientific evidence into information that communities can understand, yet many have limited familiarity with the principles of HIV prevention science and choice, and the evolving landscape of new prevention technologies. 

To strengthen the quality of public communication on HIV prevention, HEPS-Uganda partnered with the Ministry of Health and the Health Journalists Network of Uganda (HEJNU) to convene regional Media Science Cafés focused on HIV prevention, bringing together 86 journalists and media practitioners from across the country. The engagements created a platform for direct dialogue and stronger ongoing collaboration between journalists, HIV researchers, clinicians, program implementers and policy makers – enabling media professionals to deepen their understanding of LEN and other PrEP options, and Uganda’s national rollout strategy. 

The Media Science Cafés strengthened journalists’ ability to communicate accurate, balanced, and evidence-based information on HIV prevention. Participants gained a clearer understanding of the science behind LEN, the broader prevention-choice approach, and the importance of presenting HIV prevention information in ways that empower communities. Following the Cafes, journalists produced stories across print, broadcast, and digital media that expanded public access to credible information on LEN and other PrEP options. 

Public confidence in new health technologies is shaped by credible information. Strengthening the media’s capacity to report accurately on LEN and HIV prevention, in conjunction with strong, community- centered national communication materials, contributed to more informed public discourse, reduced misinformation, and supported informed decision-making among individuals considering HIV prevention options. The relationships established between journalists, researchers, and government institutions will continue to strengthen evidence-based health reporting beyond the rollout of LEN, and improve media coverage of HIV prevention, services, and science. 

Community involvement in materials design increases awareness of and demand for LEN and PrEP choice among priority populations 

Advancing Access to LEN 
Learning in Practice: Reports from our Partners – Malawi 

As part of a project to provide technical support to the Ministry of Health around LEN introduction, Pakachere led the development of awareness and demand-generation materials for LEN and PrEP choice. This work was designed and conducted using a highly consultative process in collaboration with the National AIDS Commission (NAC). To reinforce the CHOICE approach, which centers the user and promotes access to PrEP options, LEN messaging was seamlessly integrated into adapted materials previously developed for oral PrEP and cabotegravir (CAB).

The Approach

Review of existing materials: The team reviewed existing PrEP communication materials from the region and mapped existing national PrEP materials to ensure that LEN messaging was not treated as a standalone intervention but was instead positioned as part of a comprehensive HIV prevention approach. 

Creative and Message Design Workshop: Pakachere convened a stakeholder workshop — that importantly included community representation — and utilized human-centered design (HCD) methodologies to develop and adapt the existing PrEP messages and materials to include LEN. 

Through highly collaborative facilitated sessions and breakout group work, participants reviewed current PrEP evidence alongside existing operational gaps, specifically ensuring materials were understandable to all knowledge levels, combatted prevalent myths and misconceptions, and addressed service integration challenges. They also deliberated on the target audience for PrEP to decide on audience-specific and general materials that would address common gaps across all populations.  

Key takeaways included: 

  • Promote condom use in ways that resonate with audiences. For instance, one poster depicting a taxi driver showing a condom to a friend/passenger was considered not realistic.  
  • Ensure healthcare workers are wearing an easily identifiable uniform to bring confidence to the target audience.  
  • Avoid imagery that could unintentionally be interpreted as targeting men who have sex with men (MSM) only. 
  • Replace hospital-based PrEP pictures with ones showing home use. 

Chichewa PrEP Poster (left) and PrEP Choice Leaflet – English version poster (right) 

Pre-testing: Following the workshop, all draft materials underwent a rapid yet rigorous pre-testing process to ensure audience relevance and clarity. Pre-testing was conducted across six purposively selected districts: two districts from each of Malawi’s three administrative regions (South, Central, and North). Based on field feedback, the materials were refined, finalized, and officially approved for production. 

PrEP Social Media campaign 

The co-creation process was critical to developing demand creation materials that resonate with Malawi’s context, normalizes PrEP use, and reflects the realities of communities. By engaging in this consultative approach, these materials not only create demand for LEN, but strengthen communities’ familiarity with all available PrEP options, centering user choice and decision-making when accessing HIV prevention services and ultimately strengthening service delivery. 

Supporting the Ministry of Health to implement LEN in-country 

Advancing Access to LEN 
Learning in Practice: Reports from our Partners — Kenya

In advance of LEN rollout in Kenya, Lvcthealth worked closely with NASCOP and county HIV teams, to support planning and preparations at the country and facility level. Along with support to build community demand and trust, Lcvthealth provided technical support to strengthen service delivery through the development of technical assistance (TA) tool used to guide supportive supervision and TA visits across 10 counties, and directly conducting targeted supervision in Nakuru and Kiambu counties to extend technical support to these priority areas. 

Findings and lessons from the TA and supervision visits were consolidated into a report and shared with representatives from all counties during a learning forum. These learning provided critical, real-time data that could be used to improve service delivery, reinforce and share successes, and document lessons learned for future rollout of HIV prevention options. 

Key findings from the TA visits include: 

  1. Most facilities had already adopted the options approach to HIV prevention services, offering PrEP options and condoms.
  2. Some health facilities integrate PrEP services into Maternal and Child Health (MCH), Comprehensive Care Clinics (CCC), Outpatient Departments (OPD), and HTS service points. 
  3. Facilities reported increasing uptake and acceptability of LEN, particularly among populations at elevated risk, adolescents and young people, and and pregnant and breastfeeding women (PBFW). 
  4. Most facilities had healthcare workers trained on long-acting PrEP delivery, and many staff demonstrated adequate knowledge on LEN administration and HIV prevention counselling. 
  5. Counties had invested in continuing education, on-the-job mentorship, and supportive supervision activities. 

The TA visits also identified gaps and recommendations for improving implementation: 

AREA
GAPS
RECOMMENDATIONS
Service delivery
  • Lack of clear patient flow leading to long waiting times
  • Lack of LA PrEP appointment reminder system e.g. CAB month 1 return for second injection
  • Low understanding of CAB delivery among healthcare workers
  • Some providers delivering LA injectables had not been trained
  • Some facilities had not integrated PrEP in key Service Delivery Points
  • Low LEN uptake among PBFW
  • Facilities to reorganize client flow processes to improve PrEP screening, counselling, and service delivery efficiency
  • Strengthen integration of HIV prevention services
  • Develop a client appointment tracking and follow-up system
  • Identify and implement strategies for engaging PBFW on HIV prevention and PrEP uptake
  • Identify untrained providers who provide LA PrEP and train them with a focus on improving injection Technique (avoid excess drug spillage)
  • Conduct additional training or CMEs on CAB
Commodities
  • Lack of LEN in most facilities affecting PrEP choice
  • CAB being provided after facilities run out of LEN
  • LEN Commodities not accounted for in some facilities
  • Tracking Inconsistencies in the various reporting platforms: Web ADT, Kenya EMR, Facility Trackers, etc.
  • Strengthen commodity forecasting and quantification systems
  • Prioritize LEN and CAB commodities for refills in areas with high new infections
  • Strengthen Commodity management and documentation
Reporting adverse reactions
  • Gaps in reporting adverse events for LEN and CAB
  • Most clients not coming back to report adverse side effects due to long waiting time at the facility
  • Some side effects included abscess, pain, numbness, skin rashes, and joint inflammation
  • Unusual Vaginal Discharge
  • Develop a job aid for HCWs on management of Pain and other adverse effects
  • Build the injection technique among HCWs
  • Document and report pharmacovigilance issues
  • Inform and encourage clients to report the adverse events e.g. hotlines or engagement of HIV prevention champions for follow-up and escalating unreported side effects
Demand generation & community engagement
  • Some had no IEC materials; some had materials in English only
  • There were identifiable myths and misconceptions among communities, i.e. fertility, erectile dysfunction, that had not been addressed
  • Safety questions among PBFW on the use of LEN
  • Most facilities had no PrEP champions for mobilization and support for PrEP users
  • Implement targeted communication strategies for different groups
  • Engage the recently trained PrEP Champions/Ambassadors
  • Print and disseminate IEC materials
  • Develop and distribute culturally appropriate IEC materials in English and Kiswahili/Sheng
Monitoring & documentation
  • Inconsistencies of data across different reporting platforms – e.g. KenyaEMR, Pharmacy Records, Manual Registers, KHIS, etc.
  • Use of different EMR systems leading to data not reaching the national data warehouse that is critical for decision making
  • Poor data quality: incomplete entries, missing client records, unaccounted commodities, etc.
  • Some clients had been documented in a black notebook and not documented in the registers or EMR
  • Unspecified population type
  • Strengthen EMR-based documentation while reducing parallel manual systems
  • Include PrEP module in all EMR systems e.g. Tibabu
  • Conduct county-based routine data quality assessments
  • Improve internet connectivity and provision of EMR infrastructure
  • Build the capacity of HCWs to correctly utilize the EMR

To further strengthen data quality and reporting, Lvcthealth’s Monitoring and Evaluation (M&E) team provided ongoing support to health facilities to improve reporting through Electronic Medical Record (EMR) systems. Lvcthealth also participated in weekly coordination meetings convened by NASCOP, bringing together county and facility representatives. The meetings served as an important platform for reviewing reporting performance, identifying facilities requiring additional support, and coordinating targeted follow-up to address gaps in EMR-based reporting. 

Lvcthealth served an important role in supporting strong rollout of LEN, through this targeted technical assistance during the initial planning and implementation phases. As LEN introduction and PrEP scale-up in Kenya continues, implementing recommendations from the TA visits, sustained investment in healthcare worker training, accurate reporting and regular country level learning and coordination can help sustain and improve implementation.  

Global Health Watch: What a New US Congress Could Mean for Science + Global Health, America First Global Health Strategy, Measles Resurgence

Issue 94

The wave of newly elected US lawmakers with backgrounds in science and global health offers new opportunities for advocacy and oversight; a ProPublica exposé reveals nearly $40 million in federal health security awards to a company linked to the US President’s family amid the rollout of the “America First Global Health Strategy”; and the potential loss of US measles elimination status underscores the consequences of eroding trust in science and the spread of disinformation.

What a New US Congress Could Mean for Science and Global Health 

A little over a week after the US midterm elections, in which Democrats resoundingly won control of both chambers of Congress, reporting is examining what the incoming Congress in January 2027 could mean for global health funding, foreign assistance, US engagement in international health and development, science and evidence-based policy. KFF examines how Democratic control could bring greater scrutiny and oversight of global health spending, along with demands for data and accountability, while Think Global Health highlights opportunities to restore some USAID functions, reengage CDC in international health efforts, and strengthen protections for scientific research and federal health agencies. Devex highlights Congress’s legislative, budgetary and investigative powers, including potential scrutiny of the State Department’s management of foreign assistance and debate over whether to rebuild an independent aid agency. Meanwhile, Jirair Ratevosian identifies at least 28 newly elected members of Congress with public records on global health, foreign assistance or international public health cooperation, including several who have pledged to protect PEPFAR, restore USAID or strengthen international health partnerships. The New York Times also reports on a new wave of scientists and physicians elected to Congress, including epidemiologists, microbiologists and other health professionals who say they intend to challenge the administration’s science policies and bring scientific expertise to congressional oversight and policymaking. 

IMPLICATIONS: The incoming Congress presents new opportunities for accountability, funding and advocacy, including strengthening GHSD’s capacity to implement programs and rebuilding US global health and foreign assistance programs following significant dismantling over the past two years. However, the influx of new, younger lawmakers with potentially less experience in global health, foreign assistance and research underscores the need to work closely with these members and their staffs, identify emerging champions, build bipartisan support for US global health investments and leadership, and ensure that science and evidence inform policy and funding decisions. While these changes are unlikely to restore previous funding levels or reverse the restructuring of US global health assistance, they could help shape a new approach to US global health leadership and support country-led transitions. Congress is also expected to reassert its “power of the purse” and oversight authority, demanding greater accountability and transparency around administration actions affecting USAID, PEPFAR and other programs and investments. In the coming weeks, advocates will be closely watching leadership and committee assignments in both chambers, particularly those overseeing global health, foreign assistance and biomedical research.

READ: 

America First Global Health Strategy: New Awards, New Agreements Create New Concerns

The US Administration is implementing its “America First Global Health Strategy,” releasing its first awards under the US Department of State’s “Advancing Global Health Annual Program Statement” (APS). This funding mechanism is designed to complement the bilateral health agreements (MoUs) with countries and address gaps not covered by government-to-government funding. An analysis by the Health Security Policy Academy identified eight APS awards totaling $219 million in obligations as of November 6, 2026. A ProPublica investigation revealed that XpresTest, whose parent company received an investment from a fund linked to the US President’s family, was awarded $40 million in federal funding, including a $20 million APS award for outbreak response in the Democratic Republic of Congo and a separate CDC contract for Ebola screening at US airports. This award is despite XpresTest having no prior experience with Ebola or international biosecurity operations – and their CEO acknowledged that working internationally is “a new thing for us” and expressed uncertainty about being able to complete the work in the Democratic Republic of Congo: “This is a risky contract. I’m not sure we can do it.” For ongoing updates on bilateral agreements, see KFF’s America First MOU Bilateral Global Health Agreements Tracker.

IMPLICATIONS: As the “America First Global Health Strategy” moves into implementation, the first APS awards provide a significant window into how global health funding will be channeled and underscore the urgent need for transparency and accountability around how funding decisions are made, who receives funding and whether those who receive the funding have the expertise to deliver effective programs. As Emily Bass argues, the incoming Congress must prioritize dedicated oversight of the strategy, separate from investigations into the dismantling of USAID. Without this oversight, it will be increasingly difficult to assess whether US investments are delivering on their stated goals, sustaining progress against HIV and other diseases and strengthening global health security. 

READ:

Measles Resurgence Underscores the Consequences of Eroding Trust in Science

Genetic data analyzed by scientists at the request of The New York Times suggest that measles is once again endemic in the US. Measles was declared eliminated in the US 26 years ago. An expert committee of the Pan American Health Organization (PAHO) is reviewing the evidence, with a formal decision on the US’s elimination status expected on November 17. Seven countries have lost their elimination status in the past two years, including Canada, Spain and Britain, amid declining vaccination rates, vaccine hesitancy and misinformation. The US resurgence comes as the US Administration continues to undermine confidence in vaccines through contradictory messaging on vaccine safety, efforts to weaken school vaccination requirements and the touting of disinformation linking vaccines and autism.

IMPLICATIONS: The potential loss of the US’s measles elimination status shows just how quickly decades of scientific and public health progress can be reversed when trust in science erodes and misinformation and disinformation about interventions prevail. For HIV prevention and other areas of global health, scientific breakthroughs alone are insufficient to achieve public health impact; that requires sustained investment in evidence-based policies, trusted public health institutions, community engagement and equitable access to interventions. When government leaders amplify misinformation or undermine the credibility of scientific institutions, they jeopardize the foundation on which broader public health efforts depend.

READ: 

Advancing Access to LEN for PrEP in Kenya, Malawi, and Uganda

On this webinar, please join us and representatives from Ministries of Health and our partners to share their experiences with rollout and discuss how these approaches can be adapted to support LEN introduction in other countries.

Register Now

What We’re Reading

Clinical Trial Design Academy: Shaping the Future of HIV R&D

AVAC’s Clinical Trial Design Academy (CTDA), established in 2019, is the only program of its kind equipping advocates with the scientific knowledge and skillset to influence research and development (R&D) from priority setting and upstream vaccine, bNAb, ARV and MPT research through ongoing efficacy trials, results dissemination, implementation science and, ultimately, access. 

Today, the Academy’s 27 members are premier advocates who are directly influencing HIV research. Last month, the Academy gathered in Cape Town, South Africa. Read on to learn more about the Academy and the advocates who are bridging the gap between science and communities. 

CTDA Convenes to Identify Priorities and Gaps in HIV R&D 

This October, the CTDA convened to examine HIV prevention, treatment and cure resarch agendas; explore emerging trial designs and alternative approaches to evidence generation, including bioequivalence (BE) and pharmacokinetic (PK) studies; and identify gaps in research, inclusion and access. Participants reviewed R&D priorities through the lens of the Good Participatory Practice (GPP) Guidelines and identified community-driven priorities for the 2027 updated edition of the People’s Research Agenda. Jerop Limo, CTDA member and Executive Director of Ambassador for Youth and Adolescent Reproductive Health Program (AYARHEP), said of her experience on the CTDA, “I’m an all-round advocate now. The Academy puts me in the room with scientists, helps me understand their language and equips me to carry it back to the community.” 

Learn more about the CTDA from AVAC’s Grace Kumwenda 

From Capacity to Advocacy: How the CTDA Is Shaping My Role in HIV Research

CTDA member Idah Mulala of Ascend Futures Foundation in Zambia champions choice and drives meaningful youth engagement in HIV prevention research and programs. Of her experience on the CTDA, she says, “CTDA has changed how I approach my advocacy work. I no longer see community engagement as simply sharing information or ensuring that communities are consulted. I increasingly see it as ensuring that communities have the knowledge, confidence and opportunity to influence the questions researchers ask, how trials are designed and implemented, and how decisions about new health technologies are made.”  

Read Idah’s blog for more on how the CTDA is influencing research advocacy

Equipping Advocates to Shape Research Decisions and Move the Agenda Forward 

As new and emerging HIV technologies require increasingly complex trial designs, mechanisms like the CTDA matter more than ever. Communities are being asked to weigh in on scientific, ethical and implementation questions. Through technical literacy, community accountability and sustained researcher–advocate partnership, the CTDA ensures HIV prevention research remains connected to the people it is intended to serve. CTDA members have leveraged their knowledge and connections to shape HIV research trials, including the design and conduct of the ongoing EXPrESSIVE trials for monthly oral alimatravir (AMI), inclusion of adolescent and breastfeeding populations in the PURPOSE program and global guidance on analytic treatment interruption (ATI) in cure trials. 

Read more about how the CTDA is advancing a community-informed HIV agenda

Aligning HIV R&D with Community Priorities 

AVAC’s People’s Research Agenda (PRA) provides a community-driven framework for advancing equitable, accelerated research and development (R&D) and product introduction. Created in 2024 with global advocates and updated on an annual basis, the PRA tracks scientific progress, assesses how investments align with community-defined priorities and spotlights critical gaps in the HIV prevention pipeline. At the October meeting, the CTDA agreed on critical priorities and gaps across HIV prevention, treatment and cure to inform the next edition of the PRA, which is in development now. 

Explore the current PRA and watch this space for the updated PRA 

Additional Resources

From Capacity to Advocacy: How the CTDA Is Shaping My Role in HIV Research 

Idah Mulala, CTDA Member and Ascend Futures Foundation Programmes Manager, Zambia 

When I joined AVAC’s Clinical Trial Design Academy (CTDA) in 2024, I thought it would be like joining any other group where we meet, discuss, learn and move on. I did not fully appreciate how much the experience would transform my understanding of clinical trials, nor how I saw my role as an HIV prevention research advocate. 

Since joining the CTDA, my knowledge and capacity have grown tremendously. From exploring evolving clinical trial design concepts such as counterfactuals, double dummy trials and open- label studies, to understanding the basics of immune cells, broadly neutralizing antibodies (bNAbs) and correlates of protection, the journey has challenged me to think differently about clinical research and the role communities must play in it. It has also challenged me to reflect on what research advocacy looks like in the context of upstream research, particularly when some products are still in the very early stages of development. 

The biggest shift for me has been moving from implementation and access advocacy to research advocacy, where the intervention or product is not yet available. It has meant finding my voice in research conversations, which require a different set of knowledge, skills and capacity. Sometimes these conversations are harder because you are engaging with scientists, product developers and funders who speak a different language and approach issues from a different perspective. But through the CTDA engagement, I have learnt just how critical this type of advocacy is. I now have a stronger understanding of clinical trial protocols, Good Clinical Practice (GCP) and Good Participatory Practice (GPP). More importantly, I have become more confident in engaging with researchers and product developers, asking informed questions and connecting scientific discussions to the realities, priorities and concerns of the communities I represent. Through this, I have come to appreciate how important it is for communities to have a voice early in the research process, when there is still an opportunity to influence what products get developed and how they are developed, so that they respond to community needs and ultimately make a meaningful impact. 

For me, CTDA has been much more than a learning opportunity. It has changed how I approach my advocacy work. I no longer see community engagement as simply sharing information or ensuring that communities are consulted. I increasingly see it as ensuring that communities have the knowledge, confidence and opportunity to influence the questions researchers ask, how trials are designed and implemented, and how decisions about new health technologies are made. 

“For me, CTDA has been much more than a learning opportunity. It has changed how I approach my advocacy work. I no longer see community engagement as simply sharing information or ensuring that communities are consulted. I increasingly see it as ensuring that communities have the knowledge, confidence and opportunity to influence the questions researchers ask, how trials are designed and implemented, and how decisions about new health technologies are made.”

From Learning to Influence: Opportunities That Have Changed My Advocacy 

One of the clearest examples of how the CTDA has shaped my work was the opportunity to attend the Collaboration for AIDS Vaccine Discovery (CAVD) meeting, supported by the Gates Foundation in 2025. It was one of the most scientifically complex meetings I had attended to date. Yet, my foundation of research literacy from the CTDA enabled me to engage in the discussions with scientists. Having a front-row seat to these presentations helped me think through how I could help my communities back in Zambia be excited and informed about the promise of an HIV vaccine, but also to help manage expectations around the very real, difficult scientific discoveries yet to be made. Again, I was also reminded that it’s not just the late-stage, large-scale research that we need to engage with; we also need to sit with the tough, technical upstream science, and maybe most importantly, remind researchers of how it should be situated within the rest of the HIV response.  

The CTDA has taught me the importance of engagement across the entire R&D pipeline, from early clinical trials through to efficacy studies, while also thinking ahead about how to translate clinical trial results into regulatory discussions and eventual product introduction. In 2024, I had the opportunity of attending a closed partners’ meeting on the side of the HIV Research for Prevention (R4P) Conference in Peru with Gilead Sciences, the developers of lenacapavir (LEN). After tracking the progress of the PURPOSE trials through the CTDA, being in a room with the developers of a product that could transform HIV prevention was a defining moment for me. It was an opportunity to move beyond following trial updates and apply the skills I had developed, engaging directly with the people at the centre of the science. What stood out for me was that the conversations in the room were not just about the science or trial results, but also about what would happen next and what this would mean for communities. We raised questions about when there would be clarity on the price of LEN, what access would look like for communities, what would happen to trial participants after the release of trial results and how regulatory approvals could be expedited to help countries prepare for introduction and scale-up. These have become some of the most important advocacy issues around LEN in countries we come from and at the global level. 

That experience reinforced something important for me: community advocates must be equipped to do more than celebrate scientific progress. We must be able to ask – and push decision-makers to answer – difficult questions about who will benefit, under what conditions and when.  

The shift in my approach to advocacy matters in Zambia, my home country. Here, we’re in the midst of the promise of new HIV prevention options, but are still actively, continuously pushing on access and equity issues. The engagement my colleagues at Ascend Futures Foundation and I had in the PURPOSE research program gave us the solid ground to push for LEN access. Understanding and engaging with the trial process, outcomes, regulatory processes and community perceptions strengthened our positions and our power to work with Gilead and national stakeholders to translate research into reality. As a result, it’s happening faster than ever. 

What I Am Carrying Forward: Keeping Community Priorities at the Centre of Innovation

This year’s CTDA meeting was an incredible learning opportunity and a reminder of how exciting the HIV research pipeline has become across prevention, treatment and cure research. From monthly oral alimatravir (AMI) and the three-monthly vaginal ring to four-monthly injectable cabotegravir (CAB) and annual injectable LEN to investigational vaccines and bNAbs for prevention; weekly oral islatravir (ISL)/LEN combinations and long-acting CAB/rilpivirine (RPV) for treatment; and HIV cure research exploring a range of approaches to eliminate HIV from the body or achieve sustained control off therapy, the possibilities continue to expand. 

As I reflect on these developments, my biggest takeaways from the Academy go beyond the science to the communities that will drive it and shape the future of prevention, and there is still so much work ahead: 

  • In the coming months and years, advocates will need to continue playing a strong accountability role in HIV R&D. This means tracking key developments in the field, translating scientific information for communities and preparing them for what is coming, including potential new products such as AMI for prevention and ISL/LEN for treatment. At the same time, we must continue advocating for equitable access to products that have already been proven effective. 
  • Advocates also need to remain engaged in upstream HIV research, including HIV vaccines, bNAbs and multipurpose prevention technologies (MPTs). These are areas where community voices and advocacy remain critical, even when products are still in the early stages of development. Now more than ever, the field needs stronger advocacy and more voices to protect the science, influence research priorities and ensure that the needs of communities remain at the centre of HIV R&D. 
  •  The People’s Research Agenda (PRA) – a community-driven agenda for HIV research – must remain a living body of evidence that continually informs HIV research, innovation and the road that will lead to access to new HIV products. We must continue asking whether research is responding to the priorities of the people it is intended to serve. Are communities helping shape research questions? Are their preferences and lived experiences informing trial design? Are the concerns of young people, women and other communities disproportionately affected by HIV being heard? And are we thinking about access early enough, rather than waiting until a product is ready for introduction? 

I am carrying these takeaways with me into my work in Zambia. I want to continue strengthening community understanding of clinical research, supporting meaningful participation and ensuring that community priorities inform discussions with researchers, policymakers and product developers. I also want to keep connecting emerging scientific evidence to the practical issues that matter to communities, including access, affordability, informed choice and accountability. 

I want to see a future where community advocates from Zambia and across Africa are not merely invited into clinical research spaces to represent communities, but instead are equipped like I have been through the CTDA to understand the science, challenge decisions and influence how research translates into accessible prevention and treatment options. 

“I want to see a future where community advocates from Zambia and across Africa are not merely invited into clinical research spaces to represent communities, but instead are equipped like I have been through the CTDA to understand the science, challenge decisions and influence how research translates into accessible prevention and treatment options.”

Global Health Watch: A New Congress and a New Cadre of Scientific Leadership, US FDA Approves Generic LEN, Future of Global Fund

Issue 93

The US midterm elections this week brought significant changes to Congress, creating both new opportunities and uncertainties for the future of science, global health and HIV. This is a moment that is both “celebratory and scary,” with much to unpack about what a new Congress will mean for US policies and investments. With potentially more than 100 new members taking office in January, the need for education, engagement and advocacy will be critical to securing supportive policies and sustainable funding for US-led global health programs and research.

This issue examines what the election results mean for science and global health, the US FDA regulatory approval of generic lenacapavir for HIV PrEP (LEN), and Mark Dybul’s vision for the Global Fund amid shrinking resources and shifting priorities.

US Midterm Elections: A New Congress and a New Cadre of Scientific Leadership 

Tuesday’s midterm elections in the US brought seismic shifts to Congress, creating new legislative opportunities to strengthen oversight, protect investments in science and public health, and shape the future of US global health engagement. Democrats won control of both chambers of Congress, opening new avenues for congressional oversight and challenges to the administration’s science and health policy agendas. The election also brought a new wave of lawmakers with backgrounds in science, medicine and public health. The organization 314 Action, which supports Democratic candidates with science backgrounds, “hailed the victories as a ‘STEM wave,’” noting that the first Democratic physicians since the 1960s were elected to the Senate. Among the newly elected lawmakers are Congresswoman-elect Jasmine Clark of Georgia, a microbiologist and professor who has identified restoring federal scientific research funding as a priority; Congressman-elect Richard Pan of California, a pediatrician and former state senator with a strong record of advancing evidence-based vaccination policy; Senator-elect Abdul El-Sayed of Michigan, a physician with a doctorate in public health and a former assistant professor of epidemiology; and Senator-elect Annie Andrews of South Carolina, a pediatrician. At the state level, Amy Acton, who led Ohio’s COVID-19 response as director of the Ohio Department of Health, was elected governor. Also elected to Congress was longtime HIV prevention advocate Scott Wiener, who won the seat long held by retiring former House Speaker Nancy Pelosi. Congressman-elect Wiener was among the first prominent US elected officials to publicly disclose taking PrEP.

IMPLICATIONS: While science and HIV prevention may not have appeared explicitly on the ballot, the decisions this new Congress makes about research funding, public health and global health partnerships will have far-reaching consequences. With sizable Democratic majorities in both chambers and new public health leaders emerging in Congress and state governments, this week’s election could bring greater scientific expertise and support for evidence-based policymaking to debates over research funding, public health and HIV prevention. New congressional leadership and turnover on key committees, including those overseeing appropriations, foreign affairs, healthcare, scientific research and other relevant areas, create opportunities for stronger oversight, renewed investment in research and engagement with lawmakers on US global health leadership. The elections come amid mounting evidence of damage to the US research enterprise under the Trump administration. A New York Times investigation this week documents how federal workforce reductions, canceled and delayed grants, pressure on universities and political interference have disrupted scientific research. The National Institutes of Health (NIH) delayed or canceled more than 2,000 biomedical research grants, while the National Science Foundation withheld more than $1 billion in funding. Although Congress has rejected some of the administration’s largest proposed cuts, the incoming Congress has an important opportunity to protect sustained public investment and strengthen accountability. As AVAC’s Mitchell Warren shared, “Congress did not create the ‘Institute of National Health’ to advance national priorities. It created the ‘National Institutes of Health’ to center the leadership of United States science in global research, development, and science.” 

READ:  

US FDA Approves First Generic of Lenacapavir for HIV PrEP (LEN)

The US Food and Drug Administration (FDA) granted tentative approval to Dr. Reddy’s Laboratories for the first generic version of twice-yearly injectable lenacapavir (LEN) for PrEP. This comes just over two years since the first efficacy results from the PURPOSE trials, marking a significantly accelerated timeline to access. This timeline reflects early licensing by Gilead Sciences, technology transfer to generic manufacturers initiated before regulatory approval, and investments by Unitaid and the Gates Foundation to accelerate development by Dr. Reddy’s and Hetero. The approval enables procurement of generic LEN by PEPFAR and the Global Fund, with initial supplies expected to reach countries before the end of 2026. However, the approval covers only the injectable formulation, not the oral tablet loading dose needed to initiate PrEP. Generic oral approvals are anticipated in early 2027, making next year a transition period during which programs may rely on a combination of originator and generic products. 

IMPLICATIONS: The generic approval is a step toward lower prices and greater volumes of LEN, which will help with access, but regulatory approval alone will not translate into public health impact. AVAC and Access Bridge recently released Now What with Injectable LEN for PrEP, which calls for faster, more ambitious scale-up than the current Global Fund and PEPFAR commitment with the call to reach at least three million people by the end of 2027, which is “a floor, not a ceiling.” Earlier generic availability creates an opportunity to increase procurement volumes, drive down prices and expand access, but success will depend on country readiness, sustained financing, demand generation and effective delivery. Licensing and manufacturing are critical milestones, but the ultimate measure of success will be how quickly LEN reaches the people who want and need this new prevention option.

READ: 

The Global Fund’s Next Chapter

Last week we covered Mark Dybul’s appointment as executive director of the Global Fund to Fight AIDS, Tuberculosis and Malaria, which comes amid major changes to global health financing, including an 18% decrease in Global Fund financing compared to the previous three-year cycle. In new interviews with Health Policy Watch and Science, Dybul outlined his vision for the Global Fund. He describes the current moment as a “huge opportunity” to rethink global health financing and strengthen country ownership and emphasizes aligning external investments with national health plans, reducing duplicative management and reporting systems, and supporting countries to transition toward greater domestic financing. He also acknowledges the risks of reduced funding for community-led services and key populations, stressing that country ownership must include communities and civil society, not just governments. 

IMPLICATIONS: In a new analysis for ONE Data, former Global Fund Board member Jirair Ratevosian outlines ten critical questions facing the incoming leadership, including whether the Fund should expand beyond its HIV, TB and malaria mandate, how to sustain services as countries transition from donor support, and whether its procurement platform could play a larger role in accelerating access to innovations like LEN. The analysis also recalls the decline in PrEP coverage in Global Fund-supported countries from 1.4 million people in 2024 to 1.1 million in 2025. For HIV prevention, the central question is whether reforms and greater country ownership will translate into sustained financing, meaningful community leadership and faster access to prevention innovations—or leave critical services and marginalized populations further behind. 

READ: 

Webinar: How Will Power Shift With the New Congress?

Join the Positive Women’s Network and a panel featuring AVAC, AIDS United and the US People Living with HIV Caucus to examine how the midterm elections reshape political power and what the results mean for people living with HIV in the US and globally.

Register Now

What We’re Reading

Resources

Global Health Watch: State Dept. diverts millions for contraception, who’s leading US global health, new Global Fund ED, UNAIDS’ future

For nearly two years, the US Administration has ignored Congress and denied women and couples of life-saving sexual and reproductive health commodities. So this week’s breaking news that the US Department of State is shifting millions of dollars appropriated by Congress for contraception to “stem some of the bleeding they’ve caused by starting a reckless war and creating a global energy crisis” is perhaps not surprising. But it is appalling, nonetheless. With the US midterm elections happening next week, all members of Congress, irrespective of party or ideology, should be speaking up and taking back their power of the purse.

At the same time, global health leadership continues to change across the US global health agencies, with new departures at the Department of State and the Centers for Disease Control and Prevention (CDC). Meanwhile, Mark Dybul was appointed Executive Director of the Global Fund, the UNAIDS Board has rejected plans to sunset the Joint Programme, and new modeling highlights the investments needed to achieve global HIV targets by 2030. Also, this week, promising advances in mRNA cancer vaccines contrast with growing uncertainty around US vaccine policy and access.

Who Is Leading US Global Health? 

The revolving door of leadership and staffing changes across US agencies continues. Jeremy Lewin is leaving the Department of State, while Jennifer Shuford is leaving her leadership role at the Centers for Disease Control and Prevention (CDC). Also, a new Devex report provides a “who’s who” of the officials shaping and implementing the America First Global Health Strategy. It highlights the experience that remains and the significant gaps left by departing technical experts. Among those remaining is Dr. Mamadi Yilla, whose decades of experience with PEPFAR and country-level implementation are increasingly valuable; as AVAC’s Mitchell Warren told Devex, “She knows what it takes to deliver a program.” 

IMPLICATIONS: The US mid-term elections take place next week, and with further leadership changes likely post-elections, major questions remain about whether the Administration can sustain the expertise and capacity needed to translate its strategy into effective programs and ensure uninterrupted access to lifesaving services. Additionally, as the US Department of State takes on more responsibility for programs previously run by USAID and CDC, the loss of institutional knowledge and country-level experience threatens to undermine program effectiveness, continuity, oversight and accountability. This is significant as countries begin implementing their new bilateral health agreements, which require technical expertise, strong partnerships and an understanding of complex health systems.  

READ:  

Mark Dybul Appointed ED of Global Fund

Mark Dybul was appointed Executive Director of the Global Fund to Fight AIDS, Tuberculosis and Malaria (Global Fund) at a pivotal moment for global health, as funding pressures, political threats and persistent inequities threaten hard-won progress against the three diseases. Dybul previously held the position from 2013 to 2017, when he oversaw the introduction of a new evidence-based funding model and expanded the Fund’s procurement operations. He also previously led PEFPAR from 2006 to 2009. As a member of the Accra Reset high-level panel, Dybul has advocated for greater health sovereignty and changes to the international aid system. As Devex reports, he inherits unresolved questions about the Global Fund’s evaluation function, a proposed new financing mechanism and its next strategy, among many issues. As AVAC’s Suraj Madoori said in its statement, Dybul’s “global health leadership, experience and deep and durable partnerships are needed now more than ever to translate political commitments and resources into lifesaving impact, especially as the Global Fund heads into its 9th Replenishment and the organization develops its next strategy for the future beyond 2028.”  

IMPLICATIONS: The introduction of transformative new tools to prevent and treat HIV, TB and malaria provides unprecedented opportunities to accelerate progress, but it all comes in the midst of significant political and economic challenges which Dybul will need to navigate. This will require ambitious targets, affordable prices, re-commitment to community leadership and human rights, and coordinated actions to ensure these innovations reach the people and communities that need them with speed, scale and equity. As the Global Fund develops its strategy beyond 2028, Dybul will also need to define its role within a changing global health architecture, strengthen coordination with bilateral and multilateral partners, and ensure that efforts to increase country ownership do not undermine community leadership, accountability or access to lifesaving services.  

READ: 

New HIV Modeling Highlights the Stakes of UNAIDS Transformation

A new study published in PLOS Global Public Health estimates that achieving UNAIDS’ 2030 global HIV targets could reduce annual new HIV infections by 77%, from 1.3 million in 2023 to 300,000 in 2030. However, $21.9 billion annually would be required to reach these targets in low- and middle-income countries by 2030. The findings come as the UNAIDS Programme Coordinating Board (PCB) rejected a proposal to sunset the Joint Programme by the end of 2026, and instead endorsed UNAIDS’ transition to a smaller, more focused program. The proposed structure would retain a streamlined Secretariat, or hub, responsible for leadership, coordination, data and accountability, and community engagement, but would shift more technical and implementation responsibilities to UNAIDS’ UN cosponsors. A transition team is in the process of developing a fully-costed implementation plan. 

IMPLICATIONS: This new modeling data and the evolution of UNAIDS show the challenge of achieving global HIV targets as resources and institutional capacity reduce. Specifically, the transition of UNAIDS raises critical questions about whether a smaller institution can maintain the coordination, independent accountability and meaningful community leadership needed to support countries in achieving the 2030 targets.  

READ: 

Vaccine Innovation Advances as US Policy Creates New Barriers

As vaccine science continues to advance, changes to US vaccine policy continue to create major barriers to access. In the last week, new data from an experimental personalized mRNA cancer vaccine when used alongside immunotherapy, showed that the technology reduced the risk of melanoma recurrence or death by 42% over approximately two years. This demonstrates the potential of mRNA technology beyond infectious diseases, but comes as The Guardian reports sweeping changes by US Health Secretary Robert F. Kennedy Jr. that left the Advisory Committee on Immunization Practices (ACIP) unable to issue recommendations for newly approved vaccines.  

IMPLICATIONS: As science demonstrates the potential of mRNA technology, uncertainty in US vaccine policy raises broader questions about whether the institutions responsible for evaluating, recommending and delivering new vaccines can keep pace with scientific progress. Without ACIP recommendations, vaccines that have been approved by the US Food and Drug Administration (FDA) face uncertainty around insurance coverage and availability. The recently approved mRNA influenza vaccine is affected, with some patients already facing out-of-pocket costs. 

READ:

Lower-Cost HIV Tests: Advocacy for better diagnostic deals

Join AVAC, CHAI, and the WHO for this webinar to unpack some of the basics on HIV testing, pricing and procurement, and to begin a discussion about potential advocacy for change.

Register Now

What We’re Reading

Webinar Recordings

Access the recordings and resources from the webinars AVAC and partners hosted this week:

Reaching Key Populations with Long-Acting PrEP, with GBGMC

Aftershocks: Rebuilding HIV and Public Health Infrastructure, with The Choice Agenda

Watch Now

AVAC Applauds Appointment of Mark Dybul as Executive Director of the Global Fund

AVAC applauds the appointment of Mark Dybul as Executive Director of the Global Fund to Fight AIDS, Tuberculosis and Malaria. His return to the Global Fund comes at a pivotal moment for global health, as funding pressures, political threats and persistent inequities threaten hard-won progress against the three diseases.

“As a former U.S. Global AIDS Coordinator and previous Executive Director of the Global Fund, Dybul is uniquely qualified to fill this role,” said Suraj Madoori, AVAC’s Policy Advocacy Director. “His global health leadership, experience and deep and durable partnerships are needed now more than ever to translate political commitments and resources into lifesaving impact, especially as the Global Fund heads into its 9th Replenishment and the organization develops its next strategy for the future beyond 2028.”

The challenges ahead demand bold leadership and renewed urgency. The introduction of transformative new tools to prevent and treat all three diseases give us unprecedented opportunities to accelerate progress – but come in the midst of significant political and economic challenges. Realizing the promise requires ambitious targets, affordable prices, community leadership and coordinated actions to ensure scientific innovation reaches the people and communities that need them, quickly and equitably.

“Just last week, AVAC called on the Global Fund and other actors to commit to reaching at least three million people with lenacapavir for PrEP by the end of 2027, with a push to reach more people, faster,” said Mitchell Warren, Executive Director of AVAC. “With lenacapavir now and potentially alimatravir coming soon, the opportunity is now to turn scientific innovation into impact at scale. Mark Dybul’s proven track record of working with governments, communities, donors and product developers to ensure products are rolled out with speed, scale and equity makes me more optimistic than ever about the Global Fund’s role in the future of HIV prevention and in global health generally.”

AVAC is grateful to Peter Sands’ strong leadership of the Global Fund over the past eight years and looks forward to continued collaboration with Dybul and the Global Fund to advance evidence-based, community-led approaches that expand access to innovation, strengthen accountability and sustain global health progress. To deliver on this ambition, the Global Fund must strengthen and clarify new procurement mechanisms to maximize purchasing power and sustain access to lifesaving tools across HIV, TB and malaria and mobilize and leverage new resources from governments, donors, development finance institutions and other partners to close critical funding gaps, accelerate the introduction of new health technologies and protect hard-won gains. Dybul must lead the Global Fund through a changing global health architecture, defining its role and strengthening coordination across bilateral and multilateral partners to ensure that evolving funding mechanisms reinforce country ownership, community leadership and resilient health systems.